for Journals by Title or ISSN
for Articles by Keywords

Publisher: Biomed Central Ltd.   (Total: 291 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 291 Journals sorted alphabetically
Acta Neuropathologica Communications     Open Access   (Followers: 1, SJR: 2.302, h-index: 14)
Acta Veterinaria Scandinavica     Open Access   (Followers: 3, SJR: 0.425, h-index: 37)
Addiction Science & Clinical Practice     Open Access   (Followers: 7, SJR: 0.956, h-index: 22)
Advances in Simulation     Open Access   (Followers: 2)
Agriculture & Food Security     Open Access   (Followers: 14)
AIDS Research and Therapy     Open Access   (Followers: 14, SJR: 0.839, h-index: 28)
Algorithms for Molecular Biology     Open Access   (Followers: 4, SJR: 0.97, h-index: 24)
Allergy, Asthma and Clinical Immunology     Open Access   (Followers: 25, SJR: 0.782, h-index: 17)
Alzheimer's Research & Therapy     Open Access   (Followers: 6, SJR: 2.046, h-index: 25)
Animal Biotelemetry     Open Access   (Followers: 1)
Annals of Clinical Microbiology and Antimicrobials     Open Access   (Followers: 9, SJR: 0.827, h-index: 36)
Annals of General Psychiatry     Open Access   (Followers: 22, SJR: 0.727, h-index: 32)
Annals of Occupational and Environmental Medicine     Open Access   (Followers: 9)
Annals of Surgical Innovation and Research     Open Access   (Followers: 3, SJR: 0.429, h-index: 10)
Antimicrobial Resistance and Infection Control     Open Access   (Followers: 8, SJR: 1.096, h-index: 12)
Archives of Physiotherapy     Open Access   (Followers: 10)
Archives of Public Health     Open Access   (Followers: 9, SJR: 0.974, h-index: 11)
Arthritis Research & Therapy     Open Access   (Followers: 12, SJR: 1.617, h-index: 111)
Asia Pacific Family Medicine     Open Access   (SJR: 0.227, h-index: 6)
Asthma Research and Practice     Open Access   (Followers: 1)
Basic and Clinical Andrology     Open Access   (SJR: 0.195, h-index: 7)
Behavioral and Brain Functions     Open Access   (Followers: 3, SJR: 0.989, h-index: 42)
Big Data Analytics     Open Access   (Followers: 21)
BioData Mining     Open Access   (Followers: 6, SJR: 1.331, h-index: 13)
Biological Procedures Online     Open Access   (SJR: 0.664, h-index: 31)
Biological Research     Open Access   (SJR: 0.629, h-index: 41)
Biology Direct     Open Access   (Followers: 7, SJR: 3.341, h-index: 45)
Biology of Mood & Anxiety Disorders     Open Access   (Followers: 6, SJR: 0.974, h-index: 4)
Biology of Sex Differences     Open Access   (Followers: 3, SJR: 2.25, h-index: 18)
Biomarker Research     Open Access   (Followers: 2)
Biomaterials Research     Open Access   (Followers: 4)
BioMedical Engineering OnLine     Open Access   (Followers: 7, SJR: 0.531, h-index: 44)
BioPsychoSocial Medicine     Open Access   (Followers: 6, SJR: 0.638, h-index: 20)
Biotechnology for Biofuels     Open Access   (Followers: 10, SJR: 2.557, h-index: 47)
BMC Anesthesiology     Open Access   (Followers: 16, SJR: 0.655, h-index: 23)
BMC Biochemistry     Open Access   (Followers: 14, SJR: 0.792, h-index: 38)
BMC Bioinformatics     Open Access   (Followers: 133, SJR: 1.722, h-index: 144)
BMC Biology     Open Access   (Followers: 64, SJR: 3.871, h-index: 71)
BMC Biophysics     Open Access   (Followers: 5, SJR: 0.309, h-index: 9)
BMC Biotechnology     Open Access   (Followers: 15, SJR: 0.914, h-index: 54)
BMC Cancer     Open Access   (Followers: 26, SJR: 1.627, h-index: 84)
BMC Cardiovascular Disorders     Open Access   (Followers: 21, SJR: 1.023, h-index: 37)
BMC Cell Biology     Open Access   (Followers: 49, SJR: 1.486, h-index: 48)
BMC Clinical Pathology     Open Access   (Followers: 7, SJR: 0.753, h-index: 24)
BMC Complementary and Alternative Medicine     Open Access   (Followers: 13, SJR: 0.783, h-index: 53)
BMC Dermatology     Open Access   (Followers: 12, SJR: 0.854, h-index: 27)
BMC Developmental Biology     Open Access   (Followers: 14, SJR: 1.38, h-index: 55)
BMC Ear, Nose and Throat Disorders     Open Access   (Followers: 1, SJR: 0.636, h-index: 15)
BMC Ecology     Open Access   (Followers: 19, SJR: 1.433, h-index: 27)
BMC Emergency Medicine     Open Access   (Followers: 16, SJR: 0.679, h-index: 22)
BMC Endocrine Disorders     Open Access   (Followers: 6, SJR: 0.733, h-index: 25)
BMC Evolutionary Biology     Open Access   (Followers: 77, SJR: 2.053, h-index: 83)
BMC Family Practice     Open Access   (Followers: 12, SJR: 0.978, h-index: 42)
BMC Gastroenterology     Open Access   (Followers: 15, SJR: 0.999, h-index: 50)
BMC Genetics     Open Access   (Followers: 24, SJR: 1.185, h-index: 51)
BMC Genomics     Open Access   (Followers: 91, SJR: 2.343, h-index: 108)
BMC Geriatrics     Open Access   (Followers: 14, SJR: 1.025, h-index: 41)
BMC Health Services Research     Open Access   (Followers: 15, SJR: 1.128, h-index: 64)
BMC Hematology     Open Access   (Followers: 3)
BMC Immunology     Open Access   (Followers: 10, SJR: 1.087, h-index: 38)
BMC Infectious Diseases     Open Access   (Followers: 16, SJR: 1.51, h-index: 66)
BMC Intl. Health and Human Rights     Open Access   (Followers: 6, SJR: 0.878, h-index: 26)
BMC Medical Education     Open Access   (Followers: 41, SJR: 0.698, h-index: 38)
BMC Medical Ethics     Open Access   (Followers: 16, SJR: 0.859, h-index: 26)
BMC Medical Genetics     Open Access   (Followers: 7, SJR: 1.062, h-index: 52)
BMC Medical Genomics     Open Access   (Followers: 6, SJR: 1.71, h-index: 37)
BMC Medical Imaging     Open Access   (Followers: 8, SJR: 0.651, h-index: 22)
BMC Medical Informatics and Decision Making     Open Access   (Followers: 23, SJR: 1.1, h-index: 44)
BMC Medical Physics     Open Access   (Followers: 5, SJR: 0.564, h-index: 13)
BMC Medical Research Methodology     Open Access   (Followers: 8, SJR: 1.788, h-index: 67)
BMC Medicine     Open Access   (Followers: 13, SJR: 3.415, h-index: 72)
BMC Microbiology     Open Access   (Followers: 11, SJR: 1.391, h-index: 74)
BMC Molecular Biology     Open Access   (Followers: 131, SJR: 1.224, h-index: 53)
BMC Musculoskeletal Disorders     Open Access   (Followers: 17, SJR: 0.881, h-index: 61)
BMC Nephrology     Open Access   (Followers: 10, SJR: 1.113, h-index: 29)
BMC Neurology     Open Access   (Followers: 21, SJR: 1.07, h-index: 45)
BMC Neuroscience     Open Access   (Followers: 16, SJR: 1.318, h-index: 70)
BMC Nursing     Open Access   (Followers: 22, SJR: 0.561, h-index: 20)
BMC Nutrition     Open Access   (Followers: 8)
BMC Obesity     Open Access   (Followers: 6)
BMC Ophthalmology     Open Access   (Followers: 15, SJR: 0.938, h-index: 29)
BMC Oral Health     Open Access   (Followers: 5, SJR: 0.616, h-index: 28)
BMC Palliative Care     Open Access   (Followers: 23, SJR: 1.003, h-index: 25)
BMC Pediatrics     Open Access   (Followers: 15, SJR: 1.097, h-index: 47)
BMC Pharmacology     Open Access   (Followers: 3, SJR: 0.739, h-index: 30)
BMC Pharmacology & Toxicology     Open Access   (Followers: 8, SJR: 0.792, h-index: 10)
BMC Physiology     Open Access   (Followers: 4, SJR: 0.996, h-index: 30)
BMC Plant Biology     Open Access   (Followers: 14, SJR: 1.945, h-index: 71)
BMC Pregnancy and Childbirth     Open Access   (Followers: 20, SJR: 1.397, h-index: 45)
BMC Proceedings     Full-text available via subscription   (Followers: 2, SJR: 0.445, h-index: 9)
BMC Psychiatry     Open Access   (Followers: 27, SJR: 1.307, h-index: 57)
BMC Psychology     Open Access   (Followers: 17)
BMC Public Health     Open Access   (Followers: 149, SJR: 1.372, h-index: 81)
BMC Pulmonary Medicine     Open Access   (Followers: 4, SJR: 1.011, h-index: 38)
BMC Research Notes     Open Access   (Followers: 5, SJR: 0.702, h-index: 38)
BMC Sports Science, Medicine and Rehabilitation     Open Access   (Followers: 26, SJR: 0.471, h-index: 7)
BMC Structural Biology     Open Access   (Followers: 8, SJR: 1.118, h-index: 42)
BMC Surgery     Open Access   (Followers: 9, SJR: 0.675, h-index: 31)
BMC Systems Biology     Open Access   (Followers: 12, SJR: 1.493, h-index: 52)
BMC Urology     Open Access   (Followers: 14, SJR: 0.719, h-index: 27)
BMC Veterinary Research     Open Access   (Followers: 13, SJR: 0.952, h-index: 31)
BMC Women's Health     Open Access   (Followers: 10, SJR: 0.746, h-index: 30)
BMC Zoology     Open Access  
Borderline Personality Disorder and Emotion Dysregulation     Open Access   (Followers: 10)
Breast Cancer Research     Open Access   (Followers: 18, SJR: 3.133, h-index: 107)
Burns & Trauma     Open Access   (Followers: 2)
Burns & Trauma     Open Access   (Followers: 10)
Cancer & Metabolism     Open Access   (Followers: 5)
Cancer Cell Intl.     Open Access   (Followers: 4, SJR: 1.05, h-index: 33)
Cancer Imaging     Open Access   (Followers: 2, SJR: 0.67, h-index: 30)
Cancers of the Head & Neck     Open Access  
Canine Genetics and Epidemiology     Open Access   (Followers: 1)
Cardio-Oncology     Open Access  
Cardiovascular Diabetology     Open Access   (Followers: 9, SJR: 1.757, h-index: 47)
Cardiovascular Ultrasound     Open Access   (Followers: 4, SJR: 0.65, h-index: 31)
Cell Communication and Signaling     Open Access   (Followers: 2, SJR: 1.86, h-index: 37)
Cell Division     Open Access   (Followers: 1, SJR: 2.011, h-index: 32)
Cellular & Molecular Biology Letters     Hybrid Journal   (Followers: 3)
Cerebellum & Ataxias     Open Access   (Followers: 1)
Child and Adolescent Psychiatry and Mental Health     Open Access   (Followers: 22, SJR: 1.25, h-index: 25)
Chinese Medicine     Open Access   (Followers: 2, SJR: 0.655, h-index: 24)
Chinese Neurosurgical J.     Open Access  
Chiropractic & Manual Therapies     Open Access   (Followers: 5, SJR: 0.575, h-index: 19)
Cilia     Open Access   (SJR: 3.69, h-index: 12)
Clinical and Molecular Allergy     Open Access   (Followers: 5, SJR: 0.871, h-index: 24)
Clinical and Translational Allergy     Open Access   (Followers: 2, SJR: 0.119, h-index: 2)
Clinical Diabetes and Endocrinology     Open Access   (Followers: 13)
Clinical Hypertension     Open Access   (Followers: 3)
Clinical Sarcoma Research     Open Access  
Conflict and Health     Open Access   (Followers: 8, SJR: 0.831, h-index: 12)
Contraception and Reproductive Medicine     Open Access  
COPD Research and Practice     Open Access  
Cost Effectiveness and Resource Allocation     Open Access   (Followers: 4, SJR: 0.767, h-index: 26)
Critical Care     Open Access   (Followers: 53, SJR: 2.002, h-index: 112)
Current Opinion in Molecular Therapeutics     Full-text available via subscription   (Followers: 18)
Diabetology & Metabolic Syndrome     Open Access   (Followers: 8, SJR: 0.834, h-index: 23)
Diagnostic Pathology     Open Access   (Followers: 7, SJR: 0.775, h-index: 29)
Disaster and Military Medicine     Open Access   (Followers: 3)
Emerging Themes in Epidemiology     Open Access   (Followers: 13, SJR: 1.172, h-index: 24)
Environmental Health     Open Access   (Followers: 11, SJR: 1.898, h-index: 51)
Epigenetics & Chromatin     Open Access   (Followers: 8, SJR: 4.614, h-index: 26)
European J. of Medical Research     Open Access   (Followers: 1, SJR: 0.592, h-index: 46)
European Review of Aging and Physical Activity     Open Access   (Followers: 8, SJR: 0.597, h-index: 14)
Experimental & Translational Stroke Medicine     Open Access   (Followers: 8, SJR: 0.644, h-index: 13)
Experimental Hematology & Oncology     Open Access   (Followers: 3)
Eye and Vision     Open Access   (Followers: 1)
Fertility Research and Practice     Open Access   (Followers: 1)
Fibrogenesis & Tissue Repair     Open Access   (SJR: 2.496, h-index: 27)
Fisheries and Aquatic Sciences     Open Access   (Followers: 2, SJR: 0.223, h-index: 8)
Flavour     Open Access   (Followers: 4)
Fluids and Barriers of the CNS     Open Access   (Followers: 2, SJR: 2.034, h-index: 29)
Frontiers in Zoology     Open Access   (Followers: 6, SJR: 1.866, h-index: 37)
Genes and Environment     Open Access   (SJR: 0.161, h-index: 5)
Genetics Selection Evolution     Open Access   (Followers: 7, SJR: 1.341, h-index: 55)
Genome Biology     Open Access   (Followers: 29, SJR: 9.86, h-index: 168)
Genome Medicine     Open Access   (Followers: 7, SJR: 2.915, h-index: 40)
Global Health Research and Policy     Open Access   (Followers: 2)
Globalization and Health     Open Access   (Followers: 5, SJR: 1.261, h-index: 29)
Gut Pathogens     Full-text available via subscription   (Followers: 5, SJR: 1.136, h-index: 18)
Gynecologic Oncology Research and Practice     Open Access   (Followers: 1)
Harm Reduction J.     Open Access   (SJR: 1.239, h-index: 31)
Head & Face Medicine     Open Access   (Followers: 1, SJR: 0.416, h-index: 22)
Health and Quality of Life Outcomes     Open Access   (Followers: 13, SJR: 1.02, h-index: 75)
Health Research Policy and Systems     Open Access   (Followers: 11, SJR: 1.032, h-index: 28)
Hereditary Cancer in Clinical Practice     Open Access   (SJR: 0.678, h-index: 14)
Hereditas     Open Access   (Followers: 2, SJR: 0.423, h-index: 40)
Human Genomics     Open Access   (Followers: 3, SJR: 1.632, h-index: 35)
Human Resources for Health     Open Access   (Followers: 8, SJR: 1.193, h-index: 38)
Immunity & Ageing     Open Access   (Followers: 10, SJR: 1.178, h-index: 28)
Implementation Science     Open Access   (Followers: 15, SJR: 2.259, h-index: 53)
Infectious Agents and Cancer     Open Access   (SJR: 1.085, h-index: 21)
Infectious Diseases of Poverty     Open Access   (Followers: 2, SJR: 0.977, h-index: 12)
Inflammation and Regeneration     Open Access   (Followers: 1)
Intl. Breastfeeding J.     Open Access   (Followers: 22, SJR: 0.934, h-index: 23)
Intl. J. for Equity in Health     Open Access   (Followers: 7, SJR: 1.316, h-index: 31)
Intl. J. of Behavioral Nutrition and Physical Activity     Open Access   (Followers: 24, SJR: 2.216, h-index: 64)
Intl. J. of Health Geographics     Open Access   (Followers: 6, SJR: 1.216, h-index: 48)
Intl. J. of Mental Health Systems     Open Access   (Followers: 7, SJR: 0.484, h-index: 18)
Intl. J. of Pediatric Endocrinology     Open Access   (Followers: 10)
Intl. J. of Retina and Vitreous     Open Access   (Followers: 2)
Investigative Genetics     Open Access   (Followers: 1, SJR: 0.98, h-index: 13)
Irish Veterinary J.     Open Access   (Followers: 7, SJR: 0.477, h-index: 17)
Israel J. of Health Policy Research     Open Access   (SJR: 0.379, h-index: 7)
Italian J. of Pediatrics     Open Access   (Followers: 1, SJR: 0.685, h-index: 20)
J. for ImmunoTherapy of Cancer     Open Access   (Followers: 5)
J. of Angiogenesis Research     Open Access   (Followers: 2)
J. of Animal Science and Biotechnology     Open Access   (Followers: 6, SJR: 0.87, h-index: 10)
J. of Animal Science and Technology     Open Access   (Followers: 2)
J. of Biological Engineering     Open Access   (Followers: 4, SJR: 1.104, h-index: 22)
J. of Biological Research - Thessaloniki     Open Access   (SJR: 0.273, h-index: 10)
J. of Biomedical Semantics     Open Access   (Followers: 2, SJR: 0.903, h-index: 18)
J. of Cardiothoracic Surgery     Open Access   (Followers: 4, SJR: 0.622, h-index: 26)
J. of Cardiovascular Magnetic Resonance     Open Access   (Followers: 1, SJR: 3.238, h-index: 58)
J. of Clinical Movement Disorders     Open Access   (Followers: 3)
J. of Congenital Cardiology     Open Access   (Followers: 3)
J. of Diabetes and Metabolic Disorders     Open Access   (Followers: 9, SJR: 0.693, h-index: 9)
J. of Eating Disorders     Open Access   (Followers: 8, SJR: 1.047, h-index: 7)
J. of Environmental Health Science & Engineering     Open Access   (Followers: 1, SJR: 0.45, h-index: 17)
J. of Ethnobiology and Ethnomedicine     Open Access   (SJR: 1.001, h-index: 40)
J. of Experimental & Clinical Cancer Research     Open Access   (Followers: 2, SJR: 1.702, h-index: 51)

        1 2 | Last   [Sort by number of followers]   [Restore default list]

Journal Cover Biomarker Research
  [2 followers]  Follow
  This is an Open Access Journal Open Access journal
   ISSN (Online) 2050-7771
   Published by Biomed Central Ltd. Homepage  [291 journals]
  • Platelet protein biomarker panel for ovarian cancer diagnosis

    • Abstract: Background Platelets support cancer growth and spread making platelet proteins candidates in the search for biomarkers. Methods Two-dimensional (2D) gel electrophoresis, Partial Least Squares Discriminant Analysis (PLS-DA), Western blot, DigiWest. Results PLS-DA of platelet protein expression in 2D gels suggested differences between the International Federation of Gynaecology and Obstetrics (FIGO) stages III-IV of ovarian cancer, compared to benign adnexal lesions with a sensitivity of 96% and a specificity of 88%. A PLS-DA-based model correctly predicted 7 out of 8 cases of FIGO stages I-II of ovarian cancer after verification by western blot. Receiver-operator curve (ROC) analysis indicated a sensitivity of 83% and specificity of 76% at cut-off >0.5 (area under the curve (AUC) = 0.831, p < 0.0001) for detecting these cases. Validation on an independent set of samples by DigiWest with PLS-DA differentiated benign adnexal lesions and ovarian cancer, FIGO stages III-IV, with a sensitivity of 70% and a specificity of 83%. Conclusion We identified a group of platelet protein biomarker candidates that can quantify the differential expression between ovarian cancer cases as compared to benign adnexal lesions.
      PubDate: 2018-01-12
  • Development of biomarker combinations for postoperative acute kidney
           injury via Bayesian model selection in a multicenter cohort study

    • Abstract: Background Acute kidney injury (AKI) is a frequent complication of cardiac surgery. We sought prognostic combinations of postoperative biomarkers measured within 6 h of surgery, potentially in combination with cardiopulmonary bypass time (to account for the degree of insult to the kidney). We used data from a large cohort of patients and adapted methods for developing biomarker combinations to account for the multicenter design of the study. Methods The primary endpoint was sustained mild AKI, defined as an increase of 50% or more in serum creatinine over preoperative levels lasting at least 2 days during the hospital stay. Severe AKI (secondary endpoint) was defined as a serum creatinine increase of 100% or more or dialysis during hospitalization. Data were from a cohort of 1219 adults undergoing cardiac surgery at 6 medical centers; among these, 117 developed sustained mild AKI and 60 developed severe AKI. We considered cardiopulmonary bypass time and 22 biomarkers as candidate predictors. We adapted Bayesian model averaging methods to develop center-adjusted combinations for sustained mild AKI by (1) maximizing the posterior model probability and (2) retaining predictors with posterior variable probabilities above 0.5. We used resampling-based methods to avoid optimistic bias in evaluating the biomarker combinations. Results The maximum posterior model probability combination included plasma N-terminal-pro-B-type natriuretic peptide, plasma heart-type fatty acid binding protein, and change in serum creatinine from before to 0–6 h after surgery; the median probability combination additionally included plasma interleukin-6. The center-adjusted, optimism-corrected AUCs for these combinations were 0.80 (95% CI: 0.78, 0.87) and 0.81 (0.78, 0.87), respectively, for predicting sustained mild AKI, and 0.81 (0.76, 0.90) and 0.83 (0.76, 0.90), respectively, for predicting severe AKI. For these data, the Bayesian model averaging methods yielded combinations with prognostic capacity comparable to that achieved by standard frequentist methods but with more parsimonious models. Conclusions Pending external validation, the identified combinations could be used to identify individuals at high risk of AKI immediately after cardiac surgery and could facilitate clinical trials of renoprotective agents.
      PubDate: 2018-01-12
  • SALL4 as a transcriptional and epigenetic regulator in normal and leukemic

    • Abstract: Abstract In recent years, there has been substantial progress in our knowledge of the molecular pathways by which stem cell factor SALL4 regulates the embryonic stem cell (ESC) properties, developmental events, and human cancers. This review summarizes recent advances in the biology of SALL4 with a focus on its regulatory functions in normal and leukemic hematopoiesis. In the normal hematopoietic system, expression of SALL4 is mainly enriched in the bone marrow hematopoietic stem/progenitor cells (HSCs/HPCs), but is rapidly silenced following lineage differentiation. In hematopoietic malignancies, however, SALL4 expression is abnormally re-activated and linked with deteriorated disease status in patients. Further, SALL4 activation participates in the pathogenesis of tumor initiation and disease progression. Thus, a better understanding of SALL4’s biologic functions and mechanisms will facilitate development of advanced targeted anti-leukemia approaches in future.
      PubDate: 2018-01-03
  • Interleukin-10 and soluble tumor necrosis factor receptor II are potential
           biomarkers of Plasmodium falciparum infections in pregnant women: a
           case-control study from Nanoro, Burkina Faso

    • Abstract: Background Diagnosis of malaria in pregnancy is problematic due to the low sensitivity of conventional diagnostic tests (rapid diagnostic test and microscopy), which is exacerbated due to low peripheral parasite densities, and lack of clinical symptoms. In this study, six potential biomarkers to support malaria diagnosis in pregnancy were evaluated. Methods Blood samples were collected from pregnant women at antenatal clinic visits and at delivery. Microscopy and real-time PCR were performed for malaria diagnosis and biomarker analyses were performed by ELISA (interleukin 10, IL-10; tumor necrosis factor-α, TNF-α; soluble tumor necrosis factor receptor II, sTNF-RII; soluble fms-like tyrosine kinase 1, sFlt-1; leptin and apolipoprotein B, Apo-B). A placental biopsy was collected at delivery to determine placental malaria. Results IL-10 and sTNF-RII were significantly higher at all time-points in malaria-infected women (p < 0.001). Both markers were also positively associated with parasite density (p < 0.001 and p = 0.003 for IL-10 and sTNF-RII respectively). IL-10 levels at delivery, but not during pregnancy, were negatively associated with birth weight. A prediction model was created using IL-10 and sTNF-RII cut-off points. For primigravidae the model had a sensitivity of 88.9% (95%CI 45.7–98.7%) and specificity of 83.3% (95% CI 57.1–94.9%) for diagnosing malaria during pregnancy. For secundi- and multigravidae the sensitivity (81.8% and 56.5% respectively) was lower, while specificity (100.0% and 94.3% respectively) was relatively high. Sub-microscopic infections were detected in 2 out of 3 secundi- and 5 out of 12 multigravidae. Conclusions The combination of biomarkers IL-10 and sTNF-RII have the potential to support malaria diagnosis in pregnancy. Additional markers may be needed to increase sensitivity and specificity, this is of particular importance in populations with sub-microscopic infections or in whom other inflammatory diseases are prevalent.
      PubDate: 2017-12-13
  • SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative
           neoplasm overlap syndrome

    • Abstract: Abstract Myelodysplasia (MDS) /myeloproliferative neoplasm (MPN) overlap syndrome has been described since the 2001 WHO classification as disorders that have both proliferative and dysplastic changes simultaneously. Specific disorders include chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), BCR-ABL negative atypical chronic myeloid leukemia (aCML) and unclassifiable MDS/MPN (MPN/MDS-U). Recurrent gene mutations in these conditions have been described. Among them, SETBP1 mutations have been identified in up to 32% of aCML, 24% of JMML, 18% of CMML and 10% of MDS/MPN-U patients. The mutation hotspot lies in the amino acid residues 858–871 in the SETBP1 protein. SETBP1 mutations in MDS/MPN overlap syndrome is associated with accelerated transformation to leukemia and poor prognosis. In this review, we summarized the latest data on the role of SETBP1 mutations in the overlap syndrome. SETBP1 mutations may serve as a biomarker for the diagnosis and poor prognosis of the overlap syndrome.
      PubDate: 2017-12-06
  • Evaluation of two high-throughput proteomic technologies for plasma
           biomarker discovery in immunotherapy-treated melanoma patients

    • Abstract: Background Selective kinase and immune checkpoint inhibitors, and their combinations, have significantly improved the survival of patients with advanced metastatic melanoma. Not all patients will respond to treatment however, and some patients will present with significant toxicities. Hence, the identification of biomarkers is critical for the selection and management of patients receiving treatment. Biomarker discovery often involves proteomic techniques that simultaneously profile multiple proteins but few studies have compared these platforms. Methods In this study, we used the multiplex bead-based Eve Technologies Discovery assay and the aptamer-based SomaLogic SOMAscan assay to identify circulating proteins predictive of response to immunotherapy in melanoma patients treated with combination immune checkpoint inhibitors. Expression of four plasma proteins were further validated using the bead-based Millipore Milliplex assay. Results Both the Discovery and the SOMAscan assays detected circulating plasma proteins in immunotherapy-treated melanoma patients. However, these widely used assays showed limited correlation in relative protein quantification, due to differences in specificity and the dynamic range of protein detection. Protein data derived from the Discovery and Milliplex bead-based assays were highly correlated. Conclusions Our study highlights significant limitations imposed by inconsistent sensitivity and specificity due to differences in the detection antibodies or aptamers of these widespread biomarker discovery approaches. Our findings emphasize the need to improve these technologies for the accurate identification of biomarkers.
      PubDate: 2017-11-10
  • Critical appraisal of the role of serum albumin in cardiovascular disease

    • Abstract: Abstract Concentration of serum albumin (SA), a multifunctional circulatory protein, is influenced by several factors, including its synthesis rate, catabolism rate, extravascular distribution, and exogenous loss. Moreover, both nutritional status and systemic inflammation affect the synthesis of SA. Determining SA concentration aids in risk prediction in various clinical settings. It is of interest to understand the prognostic value of SA in the full spectrum of cardiovascular disease (CVD) in the era of newly developed pharmacological and interventional treatments. Proper interpretation of SA in addition to established risk factors potentially provides a better risk discrimination and thereby presents an option to modify therapeutic strategies accordingly. In this narrative review, we summarize the basic features of SA and its associated physiological functions contributing to its prognostic impacts on CVD. Finally, we discuss the prognostic role of SA in CVDs based on existing evidence.
      PubDate: 2017-11-10
  • Assessing biological and technological variability in protein levels
           measured in pre-diagnostic plasma samples of women with breast cancer

    • Abstract: Background Quantitative proteomics allows for the discovery and functional investigation of blood-based pre-diagnostic biomarkers for early cancer detection. However, a major limitation of proteomic investigations in biomarker studies remains the biological and technical variability in the analysis of complex clinical samples. Moreover, unlike ‘omics analogues such as genomics and transcriptomics, proteomics has yet to achieve reproducibility and long-term stability on a unified technological platform. Few studies have thoroughly investigated protein variability in pre-diagnostic samples of cancer patients across multiple platforms. Methods We obtained ten blood plasma “case” samples collected up to 2 years prior to breast cancer diagnosis. Each case sample was paired with a matched control plasma from a full biological sister without breast cancer. We measured protein levels using both mass-spectrometry and antibody-based technologies to: (1) assess the technical considerations in different protein assays when analyzing limited clinical samples, and (2) evaluate the statistical power of potential diagnostic analytes. Results Although we found inherent technical variation in the three assays used, we detected protein dependent biological signal from the limited samples. The three assay types yielded 32 proteins with statistically significantly (p < 1E-01) altered expression levels between cases and controls, with no proteins retaining statistical significance after false discovery correction. Conclusions Technical, practical, and study design considerations are essential to maximize information obtained in limited pre-diagnostic samples of cancer patients. This study provides a framework that estimates biological effect sizes critical for consideration in designing studies for pre-diagnostic blood-based biomarker detection.
      PubDate: 2017-10-17
  • Development of a fully automated chemiluminescence immunoassay for urine
           monomeric laminin-γ2 as a promising diagnostic tool of non-muscle
           invasive bladder cancer

    • Abstract: Background Monomeric laminin-γ2 in urine is a potential biomarker for bladder cancer. However, the current detection system uses an antibody that cannot discriminate between monomeric laminin-γ2 and the heterotrimeric γ2 chain of laminin-332, which may cause false-positive reactions. The present study aimed to develop a fully automated chemiluminescence immunoassay system using a specific monoclonal antibody against monomeric laminin-γ2. Methods In total, 237 urine specimens (84 from patients with bladder cancer, 48 from patients with benign urological disease, and 105 from healthy donors) were collected, and monomeric laminin-γ2 values in the urine were measured using a fully automated chemiluminescence immunoassay. Results The results revealed that laminin-γ2 values in patients with benign urological disease were comparable to those of healthy donors and that the chemiluminescence immunoassay’s lower limit of detection was 10 pg/mL (approximately 20-fold better than the sandwich enzyme-linked immunosorbent assay’s limit of 200 pg/mL). Moreover, the chemiluminescence immunoassay demonstrated that patients with bladder cancer, including non-muscle invasive bladder cancer (≤pT1), had higher laminin-γ2 values than patients with benign urological disease or healthy donors. Conclusions These results suggest that urine monomeric laminin-γ2 may be a promising biomarker to diagnose cases of non-muscle invasive bladder cancer using a fully automated chemiluminescence immunoassay system.
      PubDate: 2017-10-13
  • Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as
           potential biomarkers for early diagnosis of dementia disorders

    • Abstract: Background Because soluble (or secreted) amyloid precursor protein-β (sAPPβ) and -α (sAPPα) possibly reflect pathological features of Alzheimer’s disease (AD), they are potential biomarker candidates for dementia disorders, including AD and mild cognitive impairment (MCI) due to AD (MCI-AD). However, controversial results have been reported regarding their alterations in the cerebrospinal fluid (CSF) of AD and MCI-AD patients. In this study, we re-assessed the utility of sAPPα and sAPPβ in CSF as diagnostic biomarkers of dementia disorders. Methods We used a modified and sensitive detection method to analyze sAPPs levels in CSF in four groups of patients: AD (N = 33), MCI-AD (N = 17), non-AD dementia (N = 27), and disease controls (N = 19). Phosphorylated tau (p-tau), total tau, and Aβ42 were also analyzed using standard methods. Results A strong correlation was observed between sAPPα and sAPPβ, consistent with previous reports. Both sAPPα and sAPPβ were highly correlated with p-tau and total tau, suggesting that sAPPs possibly reflect neuropathological changes in the brain. Levels of sAPPα were significantly higher in MCI-AD cases compared with non-AD and disease control cases, and those of sAPPβ were also significantly higher in MCI-AD and AD cases relative to other cases. A logistic regression analysis indicated that sAPPα and sAPPβ have good discriminative power for the diagnosis of MCI-AD. Conclusions Our findings collectively suggest that both sAPPs are pathologically relevant and potentially useful biomarkers for early and accurate diagnosis of dementia disorders. We also suggest that careful measurement is important in assessing the diagnostic utility of CSF sAPPs.
      PubDate: 2017-09-22
  • Comparative study of two protocols for quantitative image-analysis of
           serotonin transporter clustering in lymphocytes, a putative biomarker of
           therapeutic efficacy in major depression

    • Abstract: Background The pattern of serotonin transporter clustering on the plasma membrane of lymphocytes extracted from human whole blood samples has been identified as a putative biomarker of therapeutic efficacy in major depression. Here we evaluated the possibility of performing a similar analysis using blood smears obtained from rats, and from control human subjects and depression patients. We hypothesized that we could optimize a protocol to make the analysis of serotonin protein clustering in blood smears comparable to the analysis of serotonin protein clustering using isolated lymphocytes. Results Our data indicate that blood smears require a longer fixation time and longer times of incubation with primary and secondary antibodies. In addition, one needs to optimize the image analysis settings for the analysis of smears. When these steps are followed, the quantitative analysis of both the number and size of serotonin transporter clusters on the plasma membrane of lymphocytes is similar using both blood smears and isolated lymphocytes. Conclusions The development of this novel protocol will greatly facilitate the collection of appropriate samples by eliminating the necessity and cost of specialized personnel for drawing blood samples, and by being a less invasive procedure. Therefore, this protocol will help us advance the validation of membrane protein clustering in lymphocytes as a biomarker of therapeutic efficacy in major depression, and bring it closer to its clinical application.
      PubDate: 2017-09-22
  • “UPRegulation” of CD47 by the endoplasmic reticulum stress pathway
           controls anti-tumor immune responses

    • Abstract: Abstract We recently demonstrated that targeting the unfolded protein response (UPR) protein GRP78 down-regulates CD47 expression, resulting in increased tumor macrophage infiltration and inhibited resistance to anti-estrogen therapy. We now show new data indicating that anti-estrogen therapy regulates CD47 expression and implicates its ligand, thrombospondin-1, in regulation of tumor macrophage infiltration. Moreover, GRP78 and CD47 co-expression is associated with poor prognosis in breast cancer patients, suggesting the existence of crosstalk between UPR and immunity that regulates therapeutic responses in breast cancer.
      PubDate: 2017-08-14
  • Tumor-associated macrophages, potential targets for cancer treatment

    • Abstract: Abstract The fact that various immune cells, including macrophages, can be found in tumor tissues has long been known. With the introduction of concept that macrophages differentiate into a classically or alternatively activated phenotype, the role of tumor-associated macrophages (TAMs) is now beginning to be elucidated. TAMs act as “protumoral macrophages”, contributing to disease progression. As the relationship between TAMs and malignant tumors becomes clearer, TAMs are beginning to be seen as potential therapeutic targets in these cases. In this review, we will discuss how TAMs can be used as therapeutic targets of cancer in clinics.
      PubDate: 2017-08-08
  • Update on the first-line treatment for Helicobacter pylori infection - a
           continuing challenge from an old enemy

    • Abstract: Abstract Because the prevalence of antibiotic resistance markedly increases with time worldwide, anti-H. pylori treatment is continuing to be a great challenge forsphysicians in clinical practice. The Real-world Practice & Expectation of Asia-Pacific Physicians and Patients in Helicobacter Pylori Eradication (REAP-HP) Survey demonstrated that the accepted minimal eradication rate of anti-H. pylori regimen in H. pylori-infected patients was 91%. The Kyoto Consensus Report on Helicobacter Pylori Gastritis also recommended that, within any region, only regimens which reliably produce eradication rates of ≥90% in that population should be used for empirical treatment. This article is aimed to review current first-line eradication regimens with a per-protocol eradication rate exceeding 90% in most geographic areas. In regions with low (≦15%) clarithromycin resistance, 14-day hybrid (or reverse hybrid), 10 ~ 14-day sequential, 7 ~ 14-day concomitant, 10 ~ 14-day bismuth quadruple or 14-day triple therapy can achieve a high eradication rate in the first-line treatment of H. pylori infection. However, in areas with high (>15%) clarithromycin resistance, standard triple therapy should be abandoned because of low eradication efficacy, and 14-day hybrid (or reverse hybrid), 10 ~ 14-day concomitant or 10 ~ 14-day bismuth quadruple therapy are the recommended regimens. If no recent data of local antibiotic resistances of H. pylori strains are available, universal high efficacy regimens such as 14-day hybrid (or reverse hybrid), concomitant or bismuth quadruple therapy can be adopted to meet the recommendation of consensus report and patients’ expectation.
      PubDate: 2017-07-11
  • Elevation of brain-enriched miRNAs in cerebrospinal fluid of patients with
           acute ischemic stroke

    • Abstract: Background The purpose of this study was to investigate the potential of cerebrospinal fluid miRNAs as diagnostic biomarkers of acute ischemic stroke using three different profiling techniques in order to identify and bypass any influence from technical variation. Methods Cerebrospinal fluid (CSF) from patients with acute ischemic stroke (n = 21) and controls (n = 21) was collected by lumbar puncture. miRNA analysis was performed with three different methods: 1) Trizol RNA extraction followed by Illumina Next Generation Sequencing (NGS) on all small RNAs, 2) Exiqon RNA extraction protocol and miRNA qPCR assays, and 3) validation of 24 selected miRNAs with Norgen Biotek RNA extraction protocol and Applied Biosystems qPCR assays. Results NGS detected 71 frequently expressed miRNAs in CSF of which brain-enriched miR-9-5p and miR-128-3p were significantly higher in CSF of stroke patients compared to controls. When dividing stroke patients into groups according to infarct size several brain-enriched miRNAs (miR-9-5p, miR-9-3p, miR-124-3p, and miR-128-3p) were elevated in patients with infarcts >2 cm3. This trend appeared in data from both NGS, qPCR (Exiqon), and qPCR (Applied Biosystems) but was only statistically significant in some of the measurement platforms. Conclusions Several brain-enriched miRNAs are elevated in the CSF three days after stroke onset, suggesting that these miRNAs reflect the brain damage caused by ischemia. The expression differences seem, however, limited to patients with larger ischemic brain injury, which argues against the use of CSF miRNAs as diagnostic biomarkers of stroke based on current methods.
      PubDate: 2017-07-11
  • Engineering CAR-T cells

    • Abstract: Abstract Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients’ or donors’ blood. After the T cells are expanded and genetically modified, they are reinfused into the patients. However, many challenges still need to be resolved in order for this technology to gain widespread adoption. In this review, we first discuss the structure and evolution of chimeric antigen receptors. We then report on the tools used for production of CAR-T cells. Finally, we address the challenges posed by CAR-T cells.
      PubDate: 2017-06-24
  • Higher serum concentrations of vimentin and DAKP1 are associated with
           aggressive breast tumour phenotypes in Ghanaian women

    • Abstract: Background Breast cancer, the most commonly diagnosed cancer among women and leading cause of cancer-related deaths worldwide, exhibits aggressive behavior in indigenous African women evidenced by high histologic grade tumours with low hormone receptor positivity. Aggressive breast cancers grow quickly, easily metastasize and recur and often have unfavourable outcomes. The current study investigated candidate genes that may regulate tumour aggression in Ghanaian women. We hypothesize that increased expression and function of certain genes other than the widely-held view attributing breast cancer aggression in African populations to their younger population age may be responsible for the aggressive nature of tumours. Methods Employing ELISA, we assayed for vimentin and death-associated protein kinase 1 (DAPK1) from thawed archived (stored at -80 °C) serum samples obtained from 40 clinically confirmed Ghanaian breast cancer patients and 40 apparently healthy controls. Patients’ clinical records and tumour parameters matching the samples were retrieved from the database of the hospital. ANOVA was used to compare means of serum protein concentration among groups while Chi-square analysis was used for the categorical data sets with p-value ≤0.05 considered significant. Multiple logistic regression analysis was conducted to determine the association between protein concentration and tumour parameters. Results Of the 80 samples, 27 (33.8%) and 53 (66.2%) were from young (<35 years) and old (≥35 years), respectively. Vimentin and DAPK1 concentration were higher in patients than controls with higher levels in “young” age group than “old” age group. Vimentin concentration was highest in grade 3 tumours followed by grade 2 and 1 but that for DAPK1 was not significant. For vimentin, tumour area strongly correlated with tumour grade (r = 0.696, p < 0.05) but weakly correlated with tumour stage (r = 0.420, p < 0.05). Patient’s age correlated with DAPK1 concentration (r = 0.393, p < 0.05). DAPK1 serum levels weakly correlated with cancer duration (r = 0.098, p = 0.27) and tumour size (r = 0.40, p < 0.05). Conclusion Serum concentration of Vimentin and DAPK1 are elevated in Ghanaian breast cancer patients. This may be partly responsible for aggressive nature of the disease among the population. Vimentin and DAPK1 should be explored further as potential breast cancer biomarkers in Africans.
      PubDate: 2017-06-09
  • Integration of a bacterial gene sequence into a chronic eosinophilic
           leukemia patient’s genome as part of a fusion gene linker

    • Abstract: Abstract Analysis of databases from the human genome project (HGP), the 1000 Genomes Project (1KGP), and The Cancer Genome Atlas (TCGA) revealed bacterial DNA integration into the human somatic genome, particularly in tumor tissues. Fusion genes have also been associated with tumorigenesis and 34 PDGFR fusion genes are linked to hematological malignancies. Here, we determined that a 17-bp homologous sequence in Marinobacter sp. Hb8, Rhodococcus fascians D188, Rhodococcus sp. PBTS2, Micrococcus luteus strain trpE16 and M. luteus NCTC 2665 integrates into the genome of a chronic eosinophilic leukemia patient as part of the linker for the novel CDK5RAP2-PDGFRα fusion gene. The resulting fusion protein that has CDK5RAP2’s self-activating domain and PDGFRa’s tyrosine kinase domain but lacks PDGFRa’s membrane-binding and ligand-dependent activation properties may act together with the integrated bacterial sequence to readily phosphorylate downstream targets, amplify proliferation signals and promote leukemic cancer progression.
      PubDate: 2017-06-05
  • Bone biomarker for the clinical assessment of osteoporosis: recent
           developments and future perspectives

    • Abstract: Abstract Bone biomarkers included formation, resorption and regulator are released during the bone remodeling processes. These bone biomarkers have attracted much attention in the clinical assessment of osteoporosis treatment in the past decade. Combination with the measurement of bone mineral density, the clinical applications of bone biomarkers have provided comprehensive information for diagnosis of osteoporosis. However, the analytical approaches of the bone biomarkers are still the challenge for further clinical trials. In this mini-review, we have introduced the functions of bone biomarkers and then recently developed techniques for bone biomarker measurements have been systematically integrated to discuss the possibility for osteoporosis assessment in the early stage.
      PubDate: 2017-05-18
  • Circulating tumor cell clusters-associated gene plakoglobin is a
           significant prognostic predictor in patients with breast cancer

    • Abstract: Background Circulating tumor cells (CTCs) are linked to metastatic relapse and are regarded as a prognostic marker for human cancer. High expression of plakoglobin, a cell adhesion protein, within the primary tumor is positively associated with CTC clusters in breast cancer. In this study, we investigated the correlation between plakoglobin expression and survival of breast cancer. Methods We evaluated 121 breast cancer patients treated with neoadjuvant chemotherapy. Expression of plakoglobin was identified by immunohistochemical staining in the cell membrane. We also examined the relation between the expression of plakoglobin and E-cadherin, an epithelial–mesenchymal transition (EMT) marker. Results Patients with high plakoglobin expression had significantly worse distant-metastasis-free survival (DMFS) (P = 0.016, log rank). Plakoglobin expression had no correlation with pathological complete response rate (P = 0.627). On univariate analysis with respect to distant metastasis, high plakoglobin expression showed worse prognosis than low plakoglobin expression [P = 0.036, hazard ratio (HR) = 3.719]. Multivariate analysis found the same result (P = 0.013, HR = 5.052). In addition, there was a significant relationship between the expression of plakoglobin and E-cadherin (P = 0.023). Conclusions Plakoglobin expression is an independent prognostic factor in patients with breast cancer, particularly for DMFS, and this is related to EMT.
      PubDate: 2017-05-12
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016